联合用药治疗头痛162例临床分析

偏头痛是一种常见病，由于病因复杂，单一药物治疗效果欠佳。我们从2000年10月-2002年10月，应用氟桂利嗪联合阿司匹林治疗81例患者疗效满意。     

七叶皂苷钠预防长春瑞宾所致静脉炎的临床观察

目的 观察应用七叶皂苷钠预防长春瑞宾所致静脉炎的临床效果。方法 33例肿瘤患者随机分为观察组和对照组。对照组：常规输入长春瑞宾前、后静脉推注地塞米松5mg；观察组：输入长春瑞宾前、后分别静脉推注七叶皂苷钠5mg。结果 观察组静脉炎发生率为13．75％，明显低于对照组的57．69％，两组比较差异有显著性（χ^2=27，P〈0．01）；静脉炎程度比较差异有显著性（χ^2=6．15，P〈0．05）。结论 合理应用七叶皂苷钠能预防长春瑞宾所致静脉炎。     

西酞普兰与氯丙咪嗪治疗颈椎间盘突出症术后抑郁焦虑症状的对照研究

目的比较西酞普兰与氯丙咪嗪治疗颈椎间盘突出症伴抑郁焦虑症状的疗效和不良反应。方法对200例颈椎间盘突出症伴抑郁焦虑症状患者分别以西酞普兰与氯丙咪嗪治疗,共治疗6周。采用汉密尔顿抑郁量表(HAMD)评定临床疗效,采用副反应量表(TESS)评定副反应。结果西酞普兰组有效率91%;氯丙咪嗪组有效率90%,2组疗效相当。但西酞普兰组起效时间平均(11.1±5.6)d,而氯丙咪嗪组平均(15.1±8.2)d,以西酞普兰组显著较快(P<0.01)。西酞普兰组不良反应发生率为13%,而氯丙咪嗪组发生率为50%,西酞普兰组不良反应发生率较低。结论西酞普兰治疗颈椎间盘突出症术后伴抑郁焦虑症状的疗效与氯丙咪嗪相当,副反应少,值得推广应用。     

NP与GP方案治疗局部晚期非小细胞肺癌近期疗效观察

目的：观察长春瑞宾（NVB）与顺铂（DDP）组成的NP方案和吉西他滨（GEM）与顺铂（DDP）组成的GP方案对局部晚期非小细胞肺癌（NSCLC）的近期疗效和毒副作用。方法：将经病理组织学或细胞学证实的45例局部晚期NSCLC患者随机分为两组,A组（NP方案组）23例,B组（GP方案组）22例,分别给予NVB＋DDP及GEM＋DDP化疗,21天为一周期。结果：A组有效率为47.8%,B组有效率为54.5%,无统计学差异（P〉0.05）。两组毒性反应均以骨髓抑制最为常见,消化道反应和静脉炎亦常见。Ⅲ～Ⅳ度白细胞减少发生率A组为34.8%,B组为31.8%;Ⅲ～Ⅳ度血小板减少发生率A组为4.3%,B组为9.1%。差异均无显著性（P〉0.05）。静脉炎发生率A组为34.8%,B组为0,差异有显著性（P〈0.05）。结论：NP方案和GP方案治疗NSCLC疗效相近,毒性反应均可耐受。     

三种头孢菌素类药物治疗社区获得性肺炎的药物经济学分析

头孢菌素抗菌谱广，抗菌作用强，组织分布广，能迅速进入血液，获得较高血药浓度，较快发挥药效，是治疗社区获得性肺炎较为常用的抗感染药物。在保障临床疗效的前提下，降低医疗成本，寻找具有最优成本一效果比的治疗方案是当前临床上需要解决的问题。作者对头孢哌酮／舒巴坦、头孢地嗪和头孢呋辛钠治疗社区获得性肺炎进行回顾性药物经济学分析，旨在为临床选择安全、有效、经济的治疗方案提供依据。     

核苷类衍生物的合成

以尿嘧啶核苷和HIV-逆转录酶抑制剂扎西他宾为先导化合物,对其5-羟基进行磷酸化修饰,然后以磷原子为桥,引入各种氨基酸酯及取代苯环,从而试图克服这类药物对核苷激酶的依赖性,提高药物的生物活性,降低药物对细胞的毒性,以此为设计思路合成了7个新的核苷类衍生物,其结构经IR,1HNMR,13CNMR,MS分析确定.     

氟桂嗪对沙鼠脑缺血后脑内转化生长因子βI型和II型受体基因表达的影响(英文)

背景:氟桂嗪和转化生长因子β(TGF-β)都具有抗脑缺血损伤作用,但两者之间是否存在某种联系,目前还不明确。目的:通过研究氟桂嗪对沙鼠脑缺血再灌注后脑内转化生长因子I型,II型受体(TβRI,II)基因表达的影响,探讨氟桂嗪与TGFβ信号转导途径在抗脑缺血损伤方面的联系。设计:随机对照的实验研究。地点和对象:实验在中南大学湘雅二医院中心实验室完成。健康雄性蒙古沙鼠60只,9月龄,体质量(90±5)g,随机分为脑缺血组、氟桂嗪治疗组、假手术组、正常对照组,其中脑缺血组、氟桂嗪治疗组各有缺血再灌6h,1,3,7d组,共计10组,每组6只。干预:夹闭双侧颈总动脉法制作沙鼠脑缺血再灌注模型,氟桂嗪治疗组实验前1d给沙鼠喂食氟桂嗪犤按20mg/(kg·d)犦。采用原位杂交检测TβRI,II基因表达情况,用苏木精-伊红染色方法观察脑组织病理变化。主要观察指标:脑组织病理变化,及脑内TβRI,IImRNAs的表达。结果:氟桂嗪治疗组在再灌注各个时间点脑组织损伤程度均明显轻于脑缺血组。各组沙鼠脑组织的神经元和胶质细胞胞浆均有TβRI,IImRNAs阳性表达。棕褐色颗粒主要位于神经元和胶质细胞胞浆中,但表达程度有所不同。假手术组的TβRI,IImRNAs的表达较正常对照组稍高但无明显差异(P>0.05)。氟桂嗪治疗组中缺血再灌注6h,1d,3dTβRI,IIm     

5-磷酸二酯酶抑制剂他达拉非与α1受体阻滞剂阿夫唑嗪在中年健康男性受试者中血液动力学的相互影响研究

ED通常与BPH相关的下尿路症状同时存在。5-磷酸二酯酶抑制剂（PDE-5）是ED的一线治疗药物。PDE-5与α1受体阻滞剂阿呋唑嗪联用，可能引起体位性低血压。为了评估5-磷酸二脂酶抑制剂他达拉非与选择性α1受体阻滞剂阿呋唑嗪（10mg／日）同时服用后血液动力学的相互作用，Giuliano等进行了一项试验。     

曲美他嗪联合阿托伐他汀治疗原发性高血压伴阵发性心房颤动的疗效观察

Objective To study the efficacy of trimctazidine combined with atorvastatin for primary hypertension with paroxysmal auricular fibrillation,and its effects on LAD and CRP. Methods 160 patients of pri-mary hypertension with paroxysmal auricular fibrillation were randomly divided into 4 groups. Forty patients were treated with amiodarone (control group),600 mg/d for the first week,400 mg/d for the second week and 200 mg/d later;40 patients were treated with atorvastatin (20 mg/d,3 times per day) in addition to amiodarone (the atorvasat-in group);40 patients were treated with trimetazidine (20 mg/d,3 times per day) in addition to armiodarone (the trimetazidine group);40 patients were treated with combination of trimetazidine and atorvastatin in addition to amiod-atone (the combination group),and the dose was the same as the above groups. The treatment was started within 24 hours of recovering from paroxysmal auricular fibrillation and lasted for 1 year. Results After 1 year there was 1 pa-the control group,and 62.5% (25/40) for the atorvasatin group,64.1% (25/39) for the trimetazidine group,and 84.6% (33/39) for the combination group. Compared to the control group,the effective rate of the 3 treatment groups were all significantly higher (X2=4.56、5.13、17.55,P<0.05). The effective rate of the combination group was significantly higher than that of the atorvasatin group and the trimetazidine group (X2=4.95、4.30,P<0.05),and there was no significant difference of effective rate between the atorvasatin group and the trimetazidine group(X2= >0.05). After treatment LAD was (40.96+1.81) mm in the control group,(38.65±1.90) mm in the atorvasatin group,(39.15±1.85)mm in the trimetazidine group,and (37.22±1.74) mm in the combination group. LAD of the 3 treatment groups were all significantly different from the control group(F=3.42,P<0.05). LAD of the combina-tion group was significantly smaller than that of the atorvasatin group and the trimetazidine group (P<0.05),and there was no significant difference of the LAD between the atorvasatin group and the trimetazidine group(P>0.05). There was no significant difference between the 4 groups on CRP before treatment (F=0.96,P>0.05). After treat-ment CRP was (8.85±1.45) mg/L in the control group,(5.96±1.26) mg/L in the atorvasatin group,(6.81± 1.37) mg/L in the trimetazidine group,and (3.75±1.15) mg/L in the combination group. CRP of the 3 treatment groups were all significantly different from the control group (F=3.63,P<0.05). CRP of the combination group was significantly lower than that of the atorvasatin group and the trimetazidine group (P<0.05),and there was no signif-icant difference of CRP between the atorvasatin group and the trimetazidine group (P>0.05). Conclusion The treatment with trmetazidine combined with atorvastatin could prevent recurrence of paroxysmal auricular fibrillation though anti-inflammatory and inhibiting the remodeling of left atrial.